Category: Corporate NewsBy Rameda AdminSeptember 9, 2024 Author: Rameda Admin Post navigationPreviousPrevious post:Earning Release One Pager 2Q24NextNext post:Rameda Completes Largest Acquisition to DateRelated PostsRameda Completes Largest Acquisition to DateSeptember 30, 2024Earning Release One Pager 2Q24August 13, 2024Rameda Announces Price Increase Approvals for All Its Top ProductsAugust 7, 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024Rameda 4Q23 Earnings ReleaseMarch 20, 2024Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023
